Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1

Conditions

Lymphoma, Large B-Cell, Diffuse 4Multiple Myeloma 3Neoplasms 2Lymphoma, Non-Hodgkin 2Lymphoma, Follicular 2Stomach Neoplasms 1Recurrence 1Neoplasm Metastasis 1Lymphoma, T-Cell, Peripheral 1Lymphoma, Mantle-Cell 1Lymphoma, Large-Cell, Anaplastic 1Lymphoma, Extranodal NK-T-Cell 1Lymphoma, B-Cell, Marginal Zone 1Lymphoma, B-Cell 1Lymphoma 1Leukemia, Lymphoid 1Leukemia, Lymphocytic, Chronic, B-Cell 1Immunoblastic Lymphadenopathy 1Enteropathy-Associated T-Cell Lymphoma 1Dendritic Cell Sarcoma, Interdigitating 1Burkitt Lymphoma 1Breast Neoplasms 1

Interventions

fludarabine phosphate 29Etoposide 26pegaspargase 24Peripheral Blood Stem Cell Transplantation 23Cyclophosphamide 23Whole-Body Irradiation 21Mycophenolic Acid 21Gemcitabine 19Busulfan 19Methotrexate 16Dexamethasone 16Tacrolimus 15Cyclosporine 14Antilymphocyte Serum 13Radiotherapy 12Oxaliplatin 10Rituximab 9Melphalan 8Asparaginase 8Doxorubicin 7Bortezomib 7spartalizumab 6Vorinostat 6Lenalidomide 6Flow Cytometry 6tislelizumab 5Vincristine 5Therapeutics 5Methylprednisolone 5Everolimus 5

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Lymphoma, Extranodal NK-T-Cell × Receptors, Chimeric Antigen × Clear all
NCT03049449 2023-01-18

T Cells Expressing a Fully-Human Anti-CD30 Chimeric Antigen Receptor for Treating CD30-Expressing Lymphomas

National Institutes of Health Clinical Center (CC)

Phase 1 Completed
26 enrolled 19 charts
Lymphoid

Immunoblastic Lymphadenopathy, Lymphoma, Large B-Cell, Diffuse, Lymphoma, T-Cell, Peripheral, Lymphoma, Large-Cell, Anaplastic, Lymphoma, Extranodal NK-T-Cell, Enteropathy-Associated T-Cell Lymphoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡